MSA United
  • en_USEN
    • fr_FRFR
    • es_ESES
    • de_DEDE
    • it_ITIT
    • pt_BRPT
  • About MSA United
  • Mission
  • MSA Research
    • Research Registry
  • Support Programs
  • Contact
Select Page
BIOHAVEN FOURNIT UNE MISE À JOUR SUR L’ESSAI DE PHASE 3 ET LE PROGRAMME SUR L’ATROPHIE MULTISYSTÉMATISÉE (AMS)

BIOHAVEN FOURNIT UNE MISE À JOUR SUR L’ESSAI DE PHASE 3 ET LE PROGRAMME SUR L’ATROPHIE MULTISYSTÉMATISÉE (AMS)

by united-for-msa | Sep 29, 2021 | Uncategorized

27/09/2021 NEW HAVEN, Conn., 27 sept. 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE : BHVN) a annoncé aujourd’hui les résultats d’une analyse ciblée d’un essai clinique sur le verdiperstat dans l’atrophie multisystématisée...
BIOHAVEN FOURNIT UNE MISE À JOUR SUR L’ESSAI DE PHASE 3 ET LE PROGRAMME SUR L’ATROPHIE MULTISYSTÉMATISÉE (AMS)

BIOHAVEN FORNISCE AGGIORNAMENTI SULLA SPERIMENTAZIONE DI FASE 3 E SUL PROGRAMMA DI ATROFIA MULTISISTEMICA (MSA)

by united-for-msa | Sep 29, 2021 | Uncategorized

09/27/2021 NEW HAVEN, Conn., 27 set 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) oggi ha annunciato i risultati ottenuti da un’analisi mirata di una sperimentazione clinica di verdiperstat nell’atrofia multisistemica (MSA)....

A BIOHAVEN FORNECE ATUALIZAÇÕES SOBRE O ENSAIO DE FASE 3 E O PROGRAMA DE ATROFIA DO SISTEMA MÚLTIPLO (MULTIPLE SYSTEM ATROPHY, MSA)

by united-for-msa | Sep 29, 2021 | Uncategorized

27/09/2021 NEW HAVEN, Conn., 27 de setembro de 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) anunciou hoje os resultados de uma análise focada de um ensaio clínico de verdiperstat na atrofia do sistema múltiplo (MSA). O...
BIOHAVEN FOURNIT UNE MISE À JOUR SUR L’ESSAI DE PHASE 3 ET LE PROGRAMME SUR L’ATROPHIE MULTISYSTÉMATISÉE (AMS)

BIOHAVEN PROPORCIONA UNA ACTUALIZACIÓN SOBRE EL ENSAYO EN FASE III Y EL PROGRAMA DE ATROFIA MULTISISTÉMICA (AMS)

by united-for-msa | Sep 29, 2021 | Uncategorized

27/09/2021 NEW HAVEN, Conn., 27 de septiembre de 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) anunció hoy los resultados de un análisis centrado en un ensayo clínico de verdiperstat en la atrofia multisistémica (AMS). El...
BIOHAVEN FOURNIT UNE MISE À JOUR SUR L’ESSAI DE PHASE 3 ET LE PROGRAMME SUR L’ATROPHIE MULTISYSTÉMATISÉE (AMS)

Biohaven Announces Disappointing News on Verdiperstat

by united-for-msa | Sep 29, 2021 | Uncategorized

VERY DISAPPOINTING NEWS FROM BIOHAVEN RE: VERDIPERSTAT (& M-STAR STUDY)Biohaven remains committed to neuroscience and to the MSA community. They intend to analyze the results further. Biohaven has met with Defeat MSA Alliance all along in this process and informed...

Recent Posts

  • BREAKING NEWS – NEW MSA RESEARCH GRANTS
  • Marks of Distinction-MSA United International Consortium
  • MSA United Global Partnerships
  • Campaña Move4MSA
  • Move 4 MSA Awareness Campaign 2022

Recent Comments

    Archives

    • March 2022
    • January 2022
    • September 2021
    • June 2021
    • May 2021
    • March 2021
    • November 2020
    • August 2020
    • July 2020
    • June 2020

    Categories

    • MSA Advocate Blog
    • MSA Patient Blog
    • MSA Research Blog
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Designed by Elegant Themes | Powered by WordPress